Ann: CEO presentation to Broker Meets Biotech - Perth, page-13

OK so I agree with everyone that this is a really solid presentation, and I've looked over a bunch of the previous company anns. I also scanned HC and saw, for example, Vipers recent rather useful analysis.

Now I know there's no such thing as a sure thing. And, obviously the risk is that when unblinded there's no difference between the arms of the study (just like any blinded trial).

But given the data shown in the presentation, and given that the control arm is something with some historical precedence (they're not bringing in patients especially for placebo treatment which is in itself a novel act) I'm finding it really hard to see how they could have stuffed up.

- the sample selection looks to be clearly differentiated
- the trial metrics are straightforwardly measurable
- the placebo is a standard treatment
- the blinded data is consistent.

Can anyone point me to a risk I've missed?